Adebrelimab and Chemoradiotherapy in High-risk LANPC
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Nanfang Hospital, Southern Medical University The First Affiliated Hospital of Xiamen University West China Hospital